AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04485585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR9006-2
Description: * Administration to the M group: 50 mg of BR9006-2 will be administered one tablet once a day, eleven-day repeated-dose~* Administration to the T+M group: 50 mg of BR9006-2 will be administered one tablet once a day, five-day repeated-dose
Study NCT01425099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: Dolutegravir is an experimental drug in the integrase inhibitor class for the treatment of HIV.
Study NCT01425099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone is a commonly used corticosteroid used for a variety of medical condiitons
Study NCT03607773 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Behavioural Intervention (MBI) group
Description: While every MBI session is different, in general they will help you develop skills in focused attention, and emotional and behavioural regulation in a group environment made up of other people with MS who may share common experiences with you. MBI sessions are group-based which means you will be attending the sessions with other people who are also in this study and facilitated by trained personnel .
Study NCT03497845 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VN
Description: 0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
Study NCT03497845 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IN
Description: 0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
Study NCT03497845 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dk/BANG
Description: 0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
Study NCT03497845 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gf/WA
Description: 0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
Study NCT03497845 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bhg/QL
Description: 0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
Study NCT03497845 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AS03 adjuvant
Description: 0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
Study NCT03497845 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59 adjuvant
Description: 0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
Study NCT03163420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac potassium
Description: Diclofenac potassium 50 mg granules for oral solution
Study NCT03163420 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Fructose
Study NCT00927563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolcapone
Description: pill, 100-300mg/day for 8 weeks
Study NCT00578643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Days -9 through -6~1 mg/kg initially (based on weight)
Study NCT00578643 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Day -5 through Day -2~Dose is based on weight:~Less than 15 kg: 3 mg~More than 15 kg to 30 kg: 5 mg~More than 30 kg: 15 mg
Study NCT00578643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days -5 through -2~50 mg/kg
Study NCT00578643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Day -5 through Day -2~30 mg/m\^2
Study NCT00578643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Cyclosporine will be administered beginning Day -2. Initial dose will 5 mg/kg infused over 24 hours.
Study NCT00578643 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Infusion
Description: Stem Cell: Either bone marrow, cord blood, or peripheral blood stem cells may be used for stem cell transplantation. It is desired to infuse: for bone marrow, nucleated cells ≥ 4 X 10\^8/kg recipient weight; for cord blood ≥ 3 X 10\^7/kg nucleated cells; for peripheral blood stem cells ≥ 1 X 10\^/kg CD34+ cells.
Study NCT01957137 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: InterStim® (Device Programming)
Study NCT01395784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone
Description: A PPARγ agonist, also marketed as Actos. Participants will be maintained on ascending doses of Placebo, pioglitazone 15 mg and 45 mg, prior to completing a lab session at the end of each dosing period.
Study NCT04409704 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: 10 Hz repetitive transcranial magnetic stimulation to dorsomedial prefrontal cortex, once daily, 5 days per week, 20-30 sessions.
Study NCT02591719 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MagPro magnetic stimulator (HF rTMS)
Description: Most activated area from fNIRS findings: Perilesional Broca's area. Use the true coil. High frequency rTMS (10Hz), Number of total stimuli: 800, Location: perilesional Broca's area, Intensity: 100% of resting motor threshold, Coil orientation: tangential to scalp, in combination with speech therapy(35-40min) after each rTMS session, Daily 10 treatment session
Study NCT02591719 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: MagPro magnetic stimulator (sham)
Description: Most activated area from fNIRS findings: Perilesional Broca's area. Use the sham coil. High frequency rTMS (10Hz), Number of total stimuli: 800, Location: perilesional Broca's area, Intensity: 100% of resting motor threshold, Coil orientation: tangential to scalp, in combination with speech therapy(35-40min) after each rTMS session, Daily 10 treatment session
Study NCT06770894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg
Description: The study population will be randomly allocated in either intervention or placebo arm (1:1). Treatment (sitagliptin 100 mg) and placebo will be provide in identical packages by an experienced independent pharmacist. The recommended intake is one tablet a day, equivalent to sitagliptin 100 mg in the active-treated group, for the duration of the study (52 weeks)
Study NCT06770894 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablets
Description: Placebo tablets 1 a day, provided in identical blisters.
Study NCT02591719 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MagPro magnetic stimulator (LF rTMS)
Description: Most activated area from fNIRS findings: Contralesional homologs of Broca's area.~Use the true coil. Low frequency rTMS (1Hz), Number of total stimuli: 1200, Location: Contralesional homologs of Broca's area (Pars triangularis), Intensity: 90% of resting motor threshold, Coil orientation: tangential to scalp, in combination with speech therapy(35-40min) after each rTMS session, Daily 10 treatment session
Study NCT01656772 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vdrive Lasso navigation
Description: Remote robotic Lasso navigation
Study NCT01656772 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Lasso navigation
Description: Manually maneuver a Lasso catheter
Study NCT02613455 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: extracorporeal shock wave therapy
Description: Following clearance, patients will be booked for ESWT in the operating room either WRNMMC or Kimbrough Ambulatory Care Center (KACC), depending on availability. Under conscious sedation, patients will receive 2000 shocks at 18-24kV, which is the standard dose utilized by our clinic in treatment of this condition. The range is necessary to account for differing size of the soft tissue envelope depending on patient habitus. The final dose utilized will be at the surgeon's discretion.
Study NCT02613455 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kenalog (triamcinolone)
Description: patients will receive an intratendinous injection in the common tendon origin of the extensor/supinators at the lateral epicondyle by an attending orthopaedic hand surgeon. The injection will contain 1cc of Kenalog-40 (triamcinolone 40mg) + 2cc lidocaine 1% (lidocaine HCl 20mg). This is the standard dose for lateral epicondylitis used routinely in the WRNMMC orthopaedic clinic.
Study NCT02613455 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine 1% (lidocaine HCl 20mg)
Description: patients will receive an intratendinous injection in the common tendon origin of the extensor/supinators at the lateral epicondyle by an attending orthopaedic hand surgeon. The injection will contain 1cc of Kenalog-40 (triamcinolone 40mg) + 2cc lidocaine 1% (lidocaine HCl 20mg). This is the standard dose for lateral epicondylitis used routinely in the WRNMMC orthopaedic clinic.
Study NCT02947867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aganirsen
Description: aganirsen antisense oligonucleotide against Insulin Receptor Substrate (IRS-1)
Study NCT02947867 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: aganirsen
Description: aganirsen antisense oligonucleotide against Insulin Receptor Substrate (IRS-1)
Study NCT04208425 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Personality
Description: The intervention includes five components: 1. An introduction to the brain, including a lesson on the concept of neuroplasticity, describing how and why our behaviors are controlled by thoughts and feelings in their brains, which have potential for change; 2. Written testimonials from older youths who describe their beliefs that people's personal traits (e.g., sadness, anxiety) are malleable, given the brain's plasticity; 3. Additional vignettes written by older youths, describing times when they used growth mindsets to persevere through social and emotional setbacks; 4. A summary of selected scientific studies suggesting that personality can, and often does, change in positive ways over time; and 5. An exercise in which the participants write notes to younger students, drawing on scientific information to describe the malleability of people's personal traits (i.e., a self-persuasion exercise).
Study NCT04208425 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sharing Feelings Intervention
Description: The ST SSI is designed to control for nonspecific aspects of intervention, including engagement in a computer program. It includes the same number of reading and writing activities as the web-based growth mindset intervention; it also mirrors the web-based growth mindset intervention as closely as possible, including vignettes written by older youths who describe times when they benefited from sharing their feelings with friends or family.
Study NCT01774422 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal CO2 removal device
Study NCT01774422 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Extracorporeal CO2 removal device
Study NCT01395784 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pioglitazone
Description: A PPARγ agonist, also marketed as Actos. Participants will be maintained on ascending doses of Placebo, pioglitazone 15 mg and 45 mg, prior to completing a lab session at the end of each dosing period.
Study NCT02900989 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Suicide screening
Description: Patients of the emergency unit usually do not pass this kind of questionnaire in the absence of warning signs. Then it could result in adverse effects on behavior and ideation.~The study had to be declared as an interventional study according to French law.
Study NCT06771271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7200220
Description: RO7200220 was administered as IVT injection.
Study NCT00412776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proxinium
Description: 700 µg Proxinium, once weekly until complete resolution of all target tumours or radiographic tumour progression
Study NCT03987204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine
Description: Ivabradine will be started and titrated to heart rate slowing of 20 bpm or greater, or an increase in pacing.
Study NCT03684135 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cosmetics
Description: Tendre Caresse au cold cream body cream from Cosmétosource Crème de douche face and body cleanser from Cosmétosource
Study NCT02628860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferinject (Ferric Carboxymaltose)
Description: Ferinject® to be administered as IV drip infusion or undiluted bolus injection with a minimum administration time of 15minutes (for 1000mg single administration) for body weight ≥50 Kg or 6 minutes (for 500mg single administration) for body weight \<50 Kg .~Study drug may be administered as IV drip infusion or IV undiluted bolus injection.
Study NCT03711903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetyl-Valine-Serine-Arginine-Arginine-Arginine-NH2 (Ac-VSRRR- NH2).
Description: The study drug, CN-105 is supplied in amber glass vials containing 4 mL of a concentrated 12.5-mg/mL clear-to-slightly-yellow solution.
Study NCT03711903 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium-chloride
Description: normal saline
Study NCT02858427 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eye tracking
Description: several oculomotor parameters will be recorded using vide-oculography techniques (eye tracking) trough different tasks: saccade, antisaccade, and picture scanning.~Saccade task: the patient is looking at a screen and is asked to fix his gaze as quickly and accurately as possible on the red dot appearing on the periphery of the screen.~Prosaccade task: the patient is looking at a screen and is asked to fix his gaze as quickly and accurately as possible on the opposite side relative to the red dot appearing on the periphery of the screen.~Picture Scanning: participant is instructed to freely watch pictures with different emotional valence.
Study NCT02858427 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: neuropsychological assessement
Description: the neuropsychological assessment aims to identify any impairment of executive functioning through several tasks: Mini mental state examination (mmse), isaac set test (STI) trail making test (TMT A and B), Grober test, Stroop test, verbal fluency, Go No Go task, memory impairment screen (MIS), picture naming test (DO30), copying figure test, digit span and categorical matching test.
Study NCT02858427 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychiatric assessment
Description: this evaluation aims to characterize the mental status of the patient. Different scales will be used: Montgomery and ASberg depression rating scale (MADRS), Columbia-suicide severity rating scale (C-SSRS), Beck depression inventory (BDI), Barratt impulsiveness scale (BIS-10), Buss and Durkee Hostility Inventory (BDHI), Balloon, analogue risk task (BART), Iowa gambling task (IGT), and Childhood trauma questionnaire (CTQ).
Study NCT02858427 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sociological interview
Description: this interview aims to characterize social interactions of the patients, their duration, their evolution and the perception of each participant on this subject.
Study NCT02949830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Givosiran
Description: Givosiran by subcutaneous (SC) injection.
Study NCT06771271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Ranibizumab was administered as IVT injection.
Study NCT02440581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alendronate
Study NCT02440581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Study NCT02440581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Study NCT00611494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MMF
Description: Gradual optimization of drug dosage, as clinically tolerated.
Study NCT00611494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EC-MPS
Description: Conversion from MMF to EC-MPS. Gradual optimization of drug dosage, as clinically tolerated.
Study NCT01811511 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chungkookjang
Study NCT01811511 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Chungkookjang
Study NCT01811511 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT01811511 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02886299 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenofibrate
Study NCT02886299 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Study NCT01422954 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine prophylaxis
Description: Standard prophylactic regime: a loading dose of 300 mg on day 14 and day 17 and then 300 mg once a week, starting on day 21, for a total duration of 13 weeks. On day 0, day 3, day 7 and day 10, this group will receive a placebo.
Study NCT01422954 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mefloquine prophylaxis
Description: Mefloquine prophylaxis, starting with a loading regime of split doses during the first three weeks: 125 mg on day 0, day 3, day 7, day 10, day 14 and day 17 and 250 mg once a week from day 21 onwards for a total duration of 13 weeks.
Study NCT01422954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mefloquine prophylaxis
Description: Mefloquine prophylaxis, starting with a loading regime of split doses during the first three weeks: 125 mg on day 0, day 3, day 7, day 10, day 14 and day 17 and 250 mg once a week from day 21 onwards for a total duration of 13 weeks.
Study NCT01422954 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Immunization
Description: Group 1 and 2 will receive three immunizations with Plasmodium falciparum infected mosquito-bites. Group 3 will receive an equal number of uninfected mosquito-bites.
Study NCT01422954 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Immunization
Description: Group 1 and 2 will receive three immunizations with Plasmodium falciparum infected mosquito-bites. Group 3 will receive an equal number of uninfected mosquito-bites.
Study NCT01422954 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunization
Description: Group 1 and 2 will receive three immunizations with Plasmodium falciparum infected mosquito-bites. Group 3 will receive an equal number of uninfected mosquito-bites.
Study NCT01422954 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Controlled Human Malaria Infection
Description: Exposure to the bites of 5 Plasmodium falciparum infected mosquitoes.
Study NCT01422954 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Controlled Human Malaria Infection
Description: Exposure to the bites of 5 Plasmodium falciparum infected mosquitoes.
Study NCT01422954 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Controlled Human Malaria Infection
Description: Exposure to the bites of 5 Plasmodium falciparum infected mosquitoes.
Study NCT01422954 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Malarone
Description: When thick smear positive, of ar day 21 after challenge, all volunteers will be treated with malarone.
Study NCT01422954 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Malarone
Description: When thick smear positive, of ar day 21 after challenge, all volunteers will be treated with malarone.
Study NCT01422954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Malarone
Description: When thick smear positive, of ar day 21 after challenge, all volunteers will be treated with malarone.
Study NCT04373460 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 convalescent plasma
Description: SARS-CoV-2 convalescent plasma (1 cup; minimum of 175 mL collected by apheresis from a volunteer who recovered from COVID-19 disease and has SARS-CoV-2 antibody titers ≥ 1:320 and after July 2021 meets FDA criteria for high titer plasma.
Study NCT04373460 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Plasma from a volunteer donor
Description: Plasma collected from a volunteer donor prior to January 1, 2020 will not be tested for SARS-CoV-2 antibodies. Plasma collected after December 31, 2019 will be confirmed as SARS-CoV-2 seronegative.
Study NCT01042444 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GARDEX™
Description: GARDEX is an embolic protection system to contain and remove embolic material (thrombus/debris) during cardiovascular interventions.~The diameter of the vessel at the site of filter basket placement should be between 3.5 mm to 6.0 mm. The GARDEX Embolic Protection System may be used with commercially available 0.014 guide wires.
Study NCT02527356 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ride-On Cars with Standing Posture (ROC-Stand)
Description: The 2-hour training session is composed of two 30-minute driving sessions and two 25-minute natural play sessions, with a 10-minute break. Every week's treatment program will be before planned and adjusted by the therapist and the caregivers through discussion and clinical observation of participant's performance in the previous session. Training will concentrate on building the concept of casual-effect on the switch and car motion, goal-oriented driving in a hospital, and upper limb use in functional tasks with driving and hand use in functional tasks for exploration in natural play session.